While the overall expression of HER3 is lower in comparison to HER2, preclinical studies showed promising efficacy and the results of a phase I/II study in HER3-positive breast cancer showed response rates of ~60% [186,187,188]. Here, ERBB2 is linked to breast carcinoma.